Hardman & Co Research
Hardman & Co Research: FY'18 sales: remains profitable despite weak UK market
Warpaint, the UK-based colour cosmetics specialist, announced its full-year results for 2018. Revenue increased by 49.2% to £48.5m (FY'17: £32.5m); however, on a like-for-like basis, revenue was down 3.2% if we assume a full-year contribution from Retra in 2017. A weak UK retail market affected sales. Internationally, though, revenue increased by 8% on a like-for-like basis; growth was particularly strong in the US and Europe. Gross margin was down by 3.3% to 35.5% for FY'18 (FY'17: 38.8%) due to product mix sold across the group during the year. Cash generation remains healthy with free cashflow of ca.£3.9m in FY'18. Warpaint announced a full-year dividend of 4.4p, up 10% on FY'17.
Please click here for the full report:
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.
About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.